CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Celularity Inc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026
$1.16−0.09 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Celularity Inc revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Degenerative Disease [Member] | $17.31M | $48.39M | $17.33M | $12.46M | $15.81M | $8.72M | 65.2% | -64.2% |
| Biobanking [Member] | $5.43M | $5.14M | $5.44M | $5.51M | $5.52M | $5.56M | 20.5% | +5.7% |
| Cell Therapy [Member] | $3.81M | $688.00K | – | – | – | – | 14.3% | +453.3% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product [Member] | $13.18M | $35.34M | $13.15M | $3.75M | $3.80M | $6.85M | 49.6% | -62.7% |
| License Royalty and Other [Member] | $7.94M | $13.74M | $4.18M | $8.71M | $12.01M | $1.87M | 29.9% | -42.2% |
| Service [Member] | $5.43M | $5.14M | $5.44M | $5.51M | $5.52M | $5.56M | 20.5% | +5.7% |
By region
From the segment and revenue-disaggregation notes of Celularity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.